Latest Regulatory Approvals News

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Peppermint Innovation Limited reported a $1.27 million net loss for the half-year ending December 2025 while achieving key milestones including activation of national payment rails in the Philippines and settling a statutory demand that led to an ASX trading suspension.

Sentinel Metals has reached a pivotal regulatory milestone as its Columbia Gold-Silver Project’s exploration amendment enters the public comment phase, paving the way for maiden drilling expected in April 2026.

Minerals 260 secures Foreign Investment Review Board approval, enabling Franco-Nevada to complete a $220 million funding package that accelerates development of the Bullabulling Gold Project.

Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.

LCL Resources has secured a transformative farm-in deal with Rio Tinto, which could see the mining giant earn up to an 80% stake in the promising Ono Project through substantial exploration funding and milestone payments.

Nexsen Limited has successfully completed a pivotal FDA Pre-Submission meeting for its StrepSure® diagnostic, significantly reducing regulatory risks and advancing its entry into the large US maternal health market.

St Barbara Limited is on track to complete key transactions with Lingbao Gold Group and Kumul Mineral Holdings, unlocking A$370 million in cash and advancing the New Simberi Gold Project.

Insignia Financial has secured a crucial regulatory approval from APRA, advancing the proposed acquisition by Daintree BidCo. The deal now moves closer to a shareholder vote scheduled for mid-April.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Cue Energy Resources has advised shareholders to hold off on any action following Horizon Oil's dispatch of a Replacement Bidder’s Statement for its unsolicited takeover offer. A formal response and recommendation from Cue’s Independent Board Committee is expected by early April.